Cost-effectiveness analysis of pharmacologic treatment of fibromyalgia in Mexico;Análisis de coste-efectividad en el tratamiento farmacológico del síndrome de fibromialgia en México

Reumatologia Clinica

Volumn 8, Issue 3, 2012, Pages 120-127

  Arreola Ornelas, Héctor ^a   Rosado Buzzo, Alfonso ^b   García, Lourdes ^b   Dorantes Aguilar, Javier ^b   Contreras Hernández, Iris ^c   Mould Quevedo, Joaquín F ^d  

^a Fundacion Mexicana para la Salud AC   (Mexico)

^b Links and Links SA   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^d PFIZER INC   (United States)

Author keywords

Cost effectiveness; Economic evaluation; Fibromyalgia syndrome; Mexico; Pregabalin

Indexed keywords

AMITRIPTYLINE; DULOXETINE; FLUOXETINE; GABAPENTIN; PARACETAMOL PLUS TRAMADOL; PREGABALIN;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; FIBROMYALGIA; HEALTH CARE; HUMAN; MEXICO; PAIN ASSESSMENT; TREATMENT OUTCOME;

ACETAMINOPHEN; AMINES; AMITRIPTYLINE; ANALGESICS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COST-BENEFIT ANALYSIS; CYCLOHEXANECARBOXYLIC ACIDS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG THERAPY, COMBINATION; FIBROMYALGIA; FLUOXETINE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MARKOV CHAINS; MEXICO; MODELS, BIOLOGICAL; MODELS, ECONOMIC; THIOPHENES; TRAMADOL; TREATMENT OUTCOME;

EID: 84860511714     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2011.12.009     Document Type: Article

References (37)

1. Schaefer C., Chandran A., Hufstader M., Baik R., McNett M., Goldenberg D., et al. The comparative burden of mild, moderate and severe fibromyalgia: results from a cross-sectional survey in the United States. Health Qual Life Outcomes 2011, 9:71.
2. Gore M, Tai KS, Chandran A, Zlateva G, Leslie D. Clinical comorbidities, treatment patterns, and healthcare costs among patients with fibromyalgia newly prescribed pregabalin or duloxetine in usual care. J Med Econ. 2012;15:19-31.
3. Gore M, Tai KS, Chandran A, Zlateva G, Leslie D. Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with fibromyalgia newly prescribed pregabalin or tricyclic antidepressants. J Med Econ. 2012;15:32-44.
4. Arnold L.M. Biology and therapy of fibromialgia. New therapies in fibromyalgia. Arthritis Res Ther 2006, 8:212.
5. Pelaez-Ballestas I., Sanin L.E., Moreno-Montoya J., Alvarez-Nemegyel J., Burgos-Vargas R., Garza-Elizondo M., et al. Epidemiology of rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology. J Rheumatol 2011, 38(Supl 86):3-6.
6. Robinson R.L., Jones M.L. In search of pharmacoeconomic evaluation for fibromyalgia treatments: a review. Expert Opin Pharmacother 2006, 7:1027-1039.
7. Bradley L.A. Pathophysiology of fibromyalgia. J Med 2009, 122(Suppl 12):S22-S35.
8. Goldenberg D.L., Burckardt C., Crofford L. Magagement of fibromyalgia syndrome. JAMA 2004, 292:2388-2395.
9. Häuser W., Bernardy N., üçeyler K., Sommer C. Treatment of fibromyalgia syndrome with antidepressants. A meta-analysis. JAMA 2009, 301:198-209.
10. Bennett R.M., Kamin M., Karin R., Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain. Am J Med 2003, 114:537-545.
11. Goldenberg D., Mayskiy M., Mossey C., Ruthazer R., Schmid C. A randomized double-blind crossover trial of fluoxetine and amitryptiline in the treatment of fibromyalgia. Arthritis Rheum 1996, 39:1852-1859.
12. Häuser W., Bernardy N., üçeyler K., Sommer C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin. A meta-analysis of randomized controlled trials. Pain 2009, 145:69-81.
13. Recla J.M. New and emerging therapeutic agents for the treatment of fibromyalgia: an update. J Pain Res 2010, 22:89-103.
14. Carville S.F., Arendt-Nielsen S., Bliddal H., Blotman F., Branco J.C., Buskila D., et al. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008, 67:536-541.
15. Bennet R. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol 2005, 23(Suppl 39):S154-S162.
16. Tarride J.E., Gordon A., Vera-Llonch M., Dukes E., Rousseau C. Cost-effectiveness of pregabalin for management of neuroplathic pain associated with peripheral neuropathy and postherpetic neuralgia: a Canadian perspective. Clin Ther 2006, 28:1922-1934.
17. Choy E, Marshall D, Gabriel ZL, Mitchell SA, Gylee E, Dakin HA. A systematic review and mixed treatment comparison of the efficacy of pharmacological treatments for fibromyalgia. Semin Arthritis Rheum. 2011;41:335-45.
18. Crofford L.J., Rowbotham M.C., Mease P.J., Russell I.J., Dworkin R.H., Corbin A.E., et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind-controlled trial. Arthritis Rheum 2005, 52:164-173.
19. Arnold L.M., Russell I.J., Diri E.W., Duan W.E., Young J.P., Sharma U., et al. A 14-week, randomized, double-blind, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia. J Pain 2008, 9:792-805.
20. Mease P.J., Russell I.J., Arnold L.M., Florian H., Young J.P, Martin S.A., et al. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008, 35:502-514.
21. Arnold L.M., Rosen A., Pritchett Y.L., D'Souza D.N., Goldstein D.J., Iyengar S., et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005, 119:5-15.
22. Arnold L.M., Lu Y., Crofford L.J., Wohlreich M., Detke M.J., Iyengar S., et al. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004, 50:2974-2984.
23. Arnold L.M., Goldenberg D.L., Stanford S.B., Lalonde J.K., Sandhu H.S., Keck P.E, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007, 56:1336-1344.
24. Hannonen P., Malminiemi K., Yli-Kertlula U., Isomeri R., Roponen P. A randomized, double-blind, placebo-controlled study of molobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol 1998, 37:1279-1286.
25. Carette S., McCain G.A., Bell D.A., Fam A.G. Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study. Arthritis Rheum 1986, 29:655-659.
26. Carette S., Bell M.J., Reynolds W.J., Haraoui B., McCain G.A., Bykerk V.P., et al. Comparasion of amitriptyline, cyclobezaprine, and placebo in the treatment of fibromialgia. A randomized, double-blind clinical trial. Arthritis Rheum 1994, 37:32-40.
27. Arnold L.M., Hess E.V., Hudson J.I., Welge J.A., Berno S.E., Keck P.E A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002, 112:191-197.
28. Wolfe F., Cathey M.A., Hawley D.J. A double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994, 23:255-259.
29. IMSS (2006 b y c). Sistema de información Médico Operativa. Sistema único de Información-Subsistema 13. Egresos hospitalarios. Coordinación de Atención Médica, IMSS, Ciudad de México.
30. Instituto Mexicano del Seguro Social Transparencia [consultado Ago 2011. Disponible en: . http://www.imss.gob.mx/transparencia/bienes.htm.
31. IMSS (2004). Bulletin of Opportune Information, IMSS. Department of Planning and Finances. January 2005, Vol. IX, N.° 01.
32. Index Mundi [consultado Nov 2011]. Disponible en: . http://www.indexmundi.com/mexico/gdp_per_capita_(ppp).html.
33. Organización Mundial de la Salud (OMS). Eligiendo intervenciones que son costo efectivas, umbrales de costo efectividad [consultado Nov 2011]. Disponible en: . http://www.who.int/choice/cost/CER_thresholds/en/index.html.
34. Choy E., Richards S., Bowrin K., Watson P., Lloyd A., Sadosky A., et al. Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective. Curr Med Opin 2010, 26:965-975.
35. Beard S.M., Rosekell N., Le T.K., Zhao Y., Coleman A., Anq D., et al. Cost effectiveness of duloxetine in the treatment of fibrimyalgia in the United States. J Med Econ 2011, 14:463-476.
36. Zijlstra T.R., Braakman-Jansen L.M.A., Taal E., Rasker J.J., Van de Laar M.A.F.J. Cost-effectiveness of Spa treatment for fibromyalgia: general health improvement is not for free. Rheumatology 2007, 46:1454-1459.
37. Rodriguez M.J., Diaz S., Vera-Llonch M., Dukes E., Rejas J. Cost-effectivenss of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpectic neuralgia. Curr Med Res Opin 2007, 23:2585-2596.